We’ve recently updated our valuation analysis.

uniQure Valuation

Is QURE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for QURE?

Other financial metrics that can be useful for relative valuation.

QURE key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue11.5x
Enterprise Value/EBITDA-4.8x
PEG Ration/a

Price to Sales Ratio vs Peers

How does QURE's PS Ratio compare to its peers?

The above table shows the PS ratio for QURE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average22.8x
RGNX REGENXBIO
2x12.5%US$938.2m
DCPH Deciphera Pharmaceuticals
8.7x27.2%US$1.1b
KROS Keros Therapeutics
63.9x84.0%US$1.3b
IDYA IDEAYA Biosciences
16.9x24.1%US$841.0m
QURE uniQure
16.4x42.3%US$1.0b

Price-To-Sales vs Peers: QURE is good value based on its Price-To-Sales Ratio (16.4x) compared to the peer average (22.8x).


Price to Earnings Ratio vs Industry

How does QURE's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a9.5%
n/an/an/a

Price-To-Sales vs Industry: QURE is expensive based on its Price-To-Sales Ratio (16.4x) compared to the US Biotechs industry average (12.1x)


Price to Sales Ratio vs Fair Ratio

What is QURE's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

QURE PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio16.4x
Fair PS Ratio0.9x

Price-To-Sales vs Fair Ratio: QURE is expensive based on its Price-To-Sales Ratio (16.4x) compared to the estimated Fair Price-To-Sales Ratio (0.9x).


Share Price vs Fair Value

What is the Fair Price of QURE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: QURE ($21.48) is trading below our estimate of fair value ($133.46)

Significantly Below Fair Value: QURE is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst QURE forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$21.48
US$52.22
+143.1%
27.7%US$94.55US$25.48n/a16
Nov ’23US$18.84
US$48.83
+159.2%
26.6%US$85.75US$24.06n/a16
Oct ’23US$18.76
US$48.79
+160.1%
27.0%US$86.28US$23.55n/a16
Sep ’23US$20.67
US$49.21
+138.1%
27.1%US$87.95US$24.00n/a16
Aug ’23US$24.12
US$51.48
+113.4%
24.1%US$87.06US$32.89n/a16
Jul ’23US$19.18
US$52.98
+176.2%
24.0%US$90.00US$34.00n/a16
Jun ’23US$14.16
US$53.39
+277.1%
24.2%US$90.98US$33.84n/a16
May ’23US$14.94
US$55.78
+273.4%
22.2%US$87.89US$33.41n/a17
Apr ’23US$19.45
US$59.30
+204.9%
24.7%US$90.37US$34.36n/a17
Mar ’23US$17.48
US$60.49
+246.0%
27.6%US$93.41US$34.00n/a17
Feb ’23US$18.29
US$65.02
+255.5%
27.1%US$96.00US$34.25n/a17
Jan ’23US$20.74
US$64.71
+212.0%
25.6%US$94.75US$39.97n/a17
Dec ’22US$26.42
US$65.86
+149.3%
25.3%US$92.80US$39.28n/a17
Nov ’22US$31.70
US$66.05
+108.4%
25.6%US$94.75US$40.11US$18.8418
Oct ’22US$32.03
US$66.22
+106.8%
26.5%US$94.24US$40.00US$18.7617
Sep ’22US$29.47
US$66.49
+125.6%
26.8%US$94.74US$38.73US$20.6717
Aug ’22US$29.01
US$66.85
+130.4%
26.9%US$95.42US$38.93US$24.1217
Jul ’22US$31.26
US$67.11
+114.7%
26.7%US$100.02US$39.16US$19.1817
Jun ’22US$34.56
US$69.00
+99.6%
25.5%US$100.98US$40.02US$14.1616
May ’22US$32.27
US$70.64
+118.9%
22.5%US$100.33US$42.00US$14.9415
Apr ’22US$34.11
US$69.39
+103.4%
22.6%US$100.33US$40.92US$19.4516
Mar ’22US$38.05
US$68.99
+81.3%
20.4%US$91.86US$42.00US$17.4816
Feb ’22US$36.00
US$68.31
+89.8%
20.4%US$92.03US$41.67US$18.2917
Jan ’22US$36.13
US$70.01
+93.8%
20.5%US$95.29US$42.00US$20.7417
Dec ’21US$49.73
US$70.47
+41.7%
19.4%US$92.98US$46.47US$26.4217
Nov ’21US$40.43
US$72.02
+78.1%
18.8%US$91.39US$46.00US$31.7014

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies